We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Wants More Safety Data on Certican Regimen
FDA Advisory Panel Wants More Safety Data on Certican Regimen
November 23, 2005
Novartis' should provide additional safety and efficacy data before the FDA approves its proposed dosing regimen for Certican, suggests the agency's Cardiovascular and Renal Drugs Advisory Committee.